|
Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth
|
18 January 2012 |
|
Nycomed reports double-digit growth across emerging markets in second quarter 2011
|
17 August 2011 |
|
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
|
16 June 2011 |
|
Nycomed continues to outperform in emerging markets in first quarter 2011
|
26 May 2011 |
|
Nycomed acquires distribution rights to product portfolio in Turkey
|
14 April 2011 |
|
REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment
|
31 March 2011 |
|
Nycomed well positioned in emerging markets
|
02 March 2011 |
|
Nycomed's novel COPD therapy roflumilast receives FDA approval
|
01 March 2011 |
|
Nycomed to acquire Colombian company Farmacol
|
06 February 2011 |
|
Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines
|
06 January 2011 |
|
Nycomed is keeping the pace in third quarter 2010
|
10 November 2010 |
|
Nycomed to accelerate expansion in China
|
01 November 2010 |
|
Global market launch of Daxas® (Roflumilast) kicks off in Germany
|
01 September 2010 |
|
Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union
|
07 July 2010 |
|
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas®
|
03 May 2010 |
|
Nycomed and Baxter receive FDA approval for TachoSil®
|
08 April 2010 |
|
Nycomed on track in 2009 with strong growth in Key Products
|
02 March 2010 |
|
Nycomed reports continued satisfactory performance in the third quarter 2009
|
13 November 2009 |
|
Nycomed reports sustained momentum in second quarter 2009
|
20 August 2009 |
|
Nycomed and Forest Laboratories to collaborate on US commercialisation of Daxas® in COPD
|
11 August 2009 |